This study was conducted to elucidate the effect of extremely low frequency electromagnetic field on keratinocyte proliferation and production of chemokines in order to evaluate a potential therapeutic use of magnetic fields in skin injuries.
Investigated chemokines were RANTES, monocyte chemoattractant protein-1, macrophage inflammatory protein-1α and interleukin-8. Their production gives an important hint of cellular immunological response. Additionally, nuclear factor kappa B was measured as it can exert influence on the cell proliferation due to the activation of signaling pathways.
The experiments were repeated at least five times in triplicate.
Exposure | Parameters |
---|---|
Exposure 1:
50 Hz
Exposure duration:
continuous for 1, 4, 12, 24, 48, 72 or 96 h
|
Frequency | 50 Hz |
---|---|
Type | |
Waveform | |
Exposure duration | continuous for 1, 4, 12, 24, 48, 72 or 96 h |
Measurand | Value | Type | Method | Mass | Remarks |
---|---|---|---|---|---|
magnetic flux density | 1 mT | effective value | measured | - | - |
After 48 hours of electromagnetic field exposure a significantly increased cell proliferation was found in exposed cells compared to control cells, while no difference in cell viability was detected.
Gene expression and release of the chemokines RANTES, monocyte chemoattractant protein-1, macrophage inflammatory protein-1α and interleukin-8 were significantly reduced after 72 hours of exposure. Nuclear factor kappa B levels became almost undetectable after only 1 hour of exposure, and were inversely correlated with cell density.
These data indicate that an extremely low frequency electromagnetic field modulates chemokine production and keratinocyte growth through inhibition of the nuclear factor kappa B signaling pathway and thus may inhibit inflammatory processes. Extremely low frequency electromagnetic field could represent an additional therapeutic approach in the treatment of skin injury.
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.